AD109

AD109 is a combination of the selective norepinephrine reuptake inhibitor atomoxetine (HY-107370) and the antimuscarinic agent aroxybutynin (HY-B0267C) . AD109 shows orally active significantly and reduce the apnea–hypopnea index[1].

Product Specifications

UNSPSC

12352005

Target

Adrenergic Receptor; mAChR

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Inflammation/Immunology

Smiles

CCN(CC)CC#CCOC([C@@](C1=CC=CC=C1)(O)C2CCCCC2)=O.CNCC[C@H](C3=CC=CC=C3)OC4=C(C)C=CC=C4

Molecular Formula

C39H52N2O4

Molecular Weight

612.84

References & Citations

[1]Apnimed reports positive topline results from second phase 3 trial of AD109, reinforcing potential of first oral pill for obstructive sleep apnea. News release. July 23, 2025. Accessed July 23, 2025.